Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02025192 · ClinicalTrials.gov registry record · Phase 1
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02025192 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 60 participants.
The verdict
NCT02025192, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended phase 2 dose (RP2D) of tucatinib (ONT-380) and to assess the safety and tolerability of tucatinib (ONT-380) combined with capecitabine alone, trastuzumab alone and with both capecitabine and trastuzumab in patients with HER2+ metastatic breast cancer.
Interventions
- DRUG Trastuzumab
- DRUG Capecitabine
- DRUG Tucatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-12-31 |
| Est. Completion | 2020-03-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02025192
The ClinicalTrials.gov registry entry for NCT02025192 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab is the first listed.
NCT02025192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02025192 about?
NCT02025192 is a clinical study titled "A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer". The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended phase 2 dose (RP2D) of tucatinib (ONT-380) and to assess the safety and tolerability of tucatinib (ONT-380) combined with capecitabine alone, trastuzumab alone and with both capecitabine and trastuzumab in pati...
What is the current status of trial NCT02025192?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2013-12-31. Estimated completion is 2020-03-16.
What interventions are being tested in trial NCT02025192?
The interventions under investigation include: Trastuzumab (DRUG), Capecitabine (DRUG), Tucatinib (DRUG).
Who is sponsoring clinical trial NCT02025192?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.